78 related articles for article (PubMed ID: 18701844)
1. [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Kamisugi K; Matsusaka S; Imada H; Shoji D; Nakamoto E; Yokokawa T; Kawakami K; Hirata Y; Nawano K; Ogawa M; Shinozaki E; Suenaga M; Mizunuma N; Hatake K; Hama T
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1331-5. PubMed ID: 18701844
[TBL] [Abstract][Full Text] [Related]
2. [Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].
Imada H; Kawakami K; Hiraoka T; Higuchi S; Takahashi G; Aoyama T; Shinozaki E; Suenaga M; Matsuzaka S; Hama T
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1425-30. PubMed ID: 17876140
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
[TBL] [Abstract][Full Text] [Related]
5. [Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Mori M; Kiba T; Oikawa M; Hokkoku K; Watanabe Y; Nakagawa T; Shintaku K; Yoshimitsu Y; Sakuma H; Ueda H; Nakai M
Gan To Kagaku Ryoho; 2009 Feb; 36(2):325-7. PubMed ID: 19223757
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
[TBL] [Abstract][Full Text] [Related]
7. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Kato T; Matsunaga Y; Motokawa S; Nakagaki S; Nagata N; Yoshida T; Muramatsu T; Kimura H; Ohashi Y; Kudou Y; Shino M; Yamazaki K; Boku N
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
[TBL] [Abstract][Full Text] [Related]
8. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Kimura T; Iwase K; Aono T; Nakai S; Fujii M; Nishikawa K; Matsuda C; Shimada K; Hirota M; Nasu S; Wada D; Hasegawa J; Tanaka Y
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
[TBL] [Abstract][Full Text] [Related]
9. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Ishizuka M; Nagata H; Takagi K; Kubota K
Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
11. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
[No Abstract] [Full Text] [Related]
12. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
Kuboki Y; Ichimura T; Ogura M; Matsuda M; Suenaga M; Shinozaki E; Matsuzaka S; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
[TBL] [Abstract][Full Text] [Related]
13. [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
Takimoto N; Sugawara S; Iida A; Sakakibara T; Mori K; Sugiura M; Yamamura K; Adachi M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):431-5. PubMed ID: 19295267
[TBL] [Abstract][Full Text] [Related]
14. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
15. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
Mandalà M; Barni S; Floriani I; Isa L; Fornarini G; Marangolo M; Mosconi S; Corsi D; Rulli E; Frontini L; Cortesi E; Zaniboni A; Aglietta M; Labianca R
Eur J Cancer; 2009 Jan; 45(1):65-73. PubMed ID: 19068274
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Punt CJ; Koopman M
J Clin Oncol; 2008 Apr; 26(11):1907-8; author reply 1908-9. PubMed ID: 18398161
[No Abstract] [Full Text] [Related]
17. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Gallego R; Codony-Servat J; García-Albéniz X; Carcereny E; Longarón R; Oliveras A; Tosca M; Augé JM; Gascón P; Maurel J
Endocr Relat Cancer; 2009 Mar; 16(1):311-7. PubMed ID: 19109398
[TBL] [Abstract][Full Text] [Related]
18. Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
Ozen A; Cicin I; Sezer A; Uzunoglu S; Saynak M; Genchellac H; Karagol H
J Cancer Res Ther; 2009; 5(2):130-2. PubMed ID: 19542672
[TBL] [Abstract][Full Text] [Related]
19. [Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Hanaka J; Takahashi M; Nakayama H; Terashima T
Gan To Kagaku Ryoho; 2016 May; 43(5):583-6. PubMed ID: 27210087
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Yamazaki K; Ariyoshi N; Miyauchi H; Ohira G; Kaneya N; Yamamoto K; Arai K; Yamazaki S; Matsubara H; Suzuki T; Ishii I
J Clin Pharm Ther; 2019 Dec; 44(6):946-951. PubMed ID: 31407827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
